FMP

FMP

Enter

CYCN - Cyclerion Therapeuti...

Financial Summary of Cyclerion Therapeutics, Inc.(CYCN), Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering

photo-url-https://financialmodelingprep.com/image-stock/CYCN.png

Cyclerion Therapeutics, Inc.

CYCN

NASDAQ

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

3.31 USD

0.19 (5.74%)

About

ceo

Dr. Regina Graul Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic neph...

CIK

0001755237

ISIN

US23255M2044

CUSIP

23255M105

Address

245 First Street

Phone

857 327 8778

Country

US

Employee

1

IPO Date

Mar 18, 2019

Summary

CIK

0001755237

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

23255M105

ISIN

US23255M2044

Country

US

Price

3.31

Beta

1.92

Volume Avg.

4.56k

Market Cap

8.97M

Shares

-

52-Week

1.7501-5.25

DCF

3.24

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.73

P/B

-

Website

https://www.cyclerion.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CYCN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep